Literature DB >> 7834187

Differential inhibition of neuronal calcium entry and [3H]-D-aspartate release by the quaternary derivatives of verapamil and emopamil.

R A Keith1, T J Mangano, P A DeFeo, G E Ernst, E J Warawa.   

Abstract

1. Verapamil and emopamil are structurally related phenylalkylamine calcium channel/5-HT2 receptor antagonists that differ in their anti-ischaemic properties in experimental studies. The quaternary ammonium derivatives of these compounds were prepared and tested in assays of neuronal voltage-sensitive calcium channel (VSCC) function to determine whether the compounds act at intra- or extracellular sites. 2. The compounds were tested in K(+)-evoked: (1) rat brain synaptosomal 45Ca2+ influx, (2) release of [3H]-D-aspartate from rat hippocampal brain slices and (3) increase of intracellular calcium in rat cortical neurones in primary culture. 3. Verapamil, emopamil and the emopamil quaternary derivative caused concentration-dependent and comparable (IC50 values approximately 30 microM) inhibition of synaptosomal 45Ca2+ influx and [3H]-D-aspartate release. The verapamil quaternary derivative was considerably less active in these assays (IC50 > 300 microM). 4. The evoked increase of intracellular calcium in cortical neurones was inhibited with the following rank order of potency (IC50 value, microM): emopamil (3.6) > verapamil (17) > emopamil quaternary derivative (38) > verapamil quaternary derivative (200). 5. The results suggest that verapamil and emopamil inhibit nerve terminal VSCC function (synaptosomal 45Ca2+ influx and [3H]-D-aspartate release) by acting at distinct intracellular and extracellular sites, respectively. Verapamil and emopamil may inhibit cell body VSCC function (evoked increase of intracellular calcium in neocortical neurones) by acting at both intracellular and extracellular sites. 6. The different 'sidedness' of action of emopamil and verapamil on nerve terminal VSCC function and/or the preferential inhibition of cell body VSCC function by emopamil may at least partially explain the relatively greater neuroprotective efficacy of emopamil in experimental models of ischaemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7834187      PMCID: PMC1510140          DOI: 10.1111/j.1476-5381.1994.tb16999.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  (S)-emopamil protects against global ischemic brain injury in rats.

Authors:  B W Lin; W D Dietrich; R Busto; M D Ginsberg
Journal:  Stroke       Date:  1990-12       Impact factor: 7.914

Review 2.  The Ca2+ channel and 5-HT2 receptor antagonist (s)-emopamil in cerebral ischaemia.

Authors:  F V Defeudis
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

3.  The effects of excitatory amino acids on intracellular calcium in single mouse striatal neurons in vitro.

Authors:  S N Murphy; S A Thayer; R J Miller
Journal:  J Neurosci       Date:  1987-12       Impact factor: 6.167

4.  S-emopamil ameliorates ischemic brain damage in rats: histological and behavioural approaches.

Authors:  F Block; R M Jaspers; C Heim; K H Sontag
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

5.  Neurotoxic action of veratridine in rat brain neuronal cultures: mechanism of neuroprotection by Ca++ antagonists nonselective for slow Ca++ channels.

Authors:  P J Pauwels; H P Van Assouw; L Peeters; J E Leysen
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

6.  Regulation of Ca++ influx into striatal neurons by kainic acid.

Authors:  S N Murphy; R J Miller
Journal:  J Pharmacol Exp Ther       Date:  1989-04       Impact factor: 4.030

7.  Evidence that uncharged verapamil inhibits myocardial contractility.

Authors:  L Cohen; D Vereault; J A Wasserstrom; G S Retzinger; F J Kezdy
Journal:  J Pharmacol Exp Ther       Date:  1987-08       Impact factor: 4.030

8.  (S)-emopamil, a novel calcium channel blocker and serotonin S2 antagonist, markedly reduces infarct size following middle cerebral artery occlusion in the rat.

Authors:  H Nakayama; M D Ginsberg; W D Dietrich
Journal:  Neurology       Date:  1988-11       Impact factor: 9.910

9.  (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 3rd communication: effect on postischemic cerebral blood flow and metabolism, and ischemic neuronal cell death.

Authors:  L Szabo; H P Hofmann
Journal:  Arzneimittelforschung       Date:  1989-03

10.  (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 2nd communication: brain penetration, cerebral vascular and metabolic effects.

Authors:  L Szabo
Journal:  Arzneimittelforschung       Date:  1989-03
View more
  2 in total

1.  From the Cover: BDE-47 and BDE-49 Inhibit Axonal Growth in Primary Rat Hippocampal Neuron-Glia Co-Cultures via Ryanodine Receptor-Dependent Mechanisms.

Authors:  Hao Chen; Karin M Streifel; Vikrant Singh; Dongren Yang; Linley Mangini; Heike Wulff; Pamela J Lein
Journal:  Toxicol Sci       Date:  2017-04-01       Impact factor: 4.849

2.  Antiarrhythmic calcium channel blocker verapamil inhibits trek currents in sympathetic neurons.

Authors:  S Herrera-Pérez; L Rueda-Ruzafa; A Campos-Ríos; D Fernández-Fernández; J A Lamas
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.